Welcome to our dedicated page for OMADA HEALTH SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health, Inc. director Jeryl L. Hilleman reported an updated equity holding following a restricted stock unit grant and a correction to a prior filing. On 10/05/2025, Hilleman was granted 1,081 restricted stock units (RSUs) of Omada Health common stock under the company’s Non-Employee Director Compensation Program, in lieu of cash retainer fees, at a reported price of $0 per share. Each RSU represents the right to receive one share of common stock, with settlement timing determined under the program or as selected by the director. After this transaction, Hilleman beneficially owned 11,193 shares of common stock. The amendment notes that the original report overstated both the amount of securities acquired and beneficially owned by 45 shares, and this filing corrects those errors.
Omada Health, Inc. Chief Financial Officer Steven L. Cook reported a sale of 4,211 shares of the company’s common stock on 12/10/2025 at a weighted average price of $15.3657 per share. The sale was coded as an open market or private sale transaction and was made pursuant to a Rule 10b5-1 trading plan adopted by Cook on 08/15/2025.
The transaction was executed in multiple trades at prices ranging from $15.24 to $15.55 per share. Following this sale, Cook beneficially owns 57,566 shares of Omada Health common stock in direct ownership.
Omada Health, Inc. reported an insider stock sale by Chief Executive Officer and director Sean P. Duffy. On December 10, 2025, he sold 9,266 shares of common stock at a weighted average price of $15.3657 per share in an open-market transaction coded S.
The sale was made under a Rule 10b5-1 trading plan adopted on August 15, 2025. After this transaction, Duffy beneficially owned 126,644 shares directly and 861,109 shares indirectly through family trusts for the benefit of his family members, and he disclaims beneficial ownership of the trust-held shares except to the extent of his pecuniary interest.
Omada Health (OMDA) reported Q3 2025 results showing strong top-line growth and improved losses. Revenue for the three months ended September 30, 2025 rose to $68.0 million from $45.5 million a year ago, driven by services revenue of $62.9 million and hardware revenue of $5.1 million. Gross profit increased to $45.1 million from $28.6 million.
Operating loss narrowed to $2.5 million from $8.5 million, and net loss improved to $3.2 million from $9.2 million. Basic and diluted net loss per share was $(0.06) (vs. $(1.18)), reflecting a larger post‑IPO share count.
Liquidity strengthened materially. Cash and cash equivalents were $198.6 million at quarter‑end (vs. $76.4 million at December 31, 2024). The company completed an IPO on June 9, 2025, generating $151.6 million in net proceeds and subsequently repaid its MidCap term loan and revolver, recording a $2.1 million loss on debt extinguishment. Accounts receivable increased to $41.4 million, with significant contributions from affiliates of The Cigna Group. Shares outstanding were 57,908,047 as of November 5, 2025.
Omada Health, Inc. (OMDA) reported that it issued a press release announcing financial results for the three months ended September 30, 2025. The press release is furnished as Exhibit 99.1 to a Form 8-K under Item 2.02 and, as stated, is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as specifically referenced.
Jonathan D. Root, a director of Omada Health, Inc. (OMDA), reported the receipt of 657 restricted stock units (RSUs) on
Insider transaction summary: A Form 4 shows that Trevor Fetter, a director of Omada Health, Inc. (OMDA), was granted 712 restricted stock units (RSUs) on
The form was signed by an attorney-in-fact on
Insider transaction by Omada Health director Jeryl L. Hilleman: the filing reports that on
Steven L. Cook, Chief Financial Officer of Omada Health, Inc. (OMDA), reported a sale of shares on 09/05/2025. The Form 4 shows a disposition of 2,006 shares of common stock at a price of $24.28 per share, leaving Mr. Cook with 63,783 shares owned directly after the transaction. The filing was signed by an attorney-in-fact on 09/09/2025.
Sean P. Duffy, Omada Health insider sale disclosed. The filing shows that on 09/05/2025 Mr. Duffy, who serves as Chief Executive Officer and a Director, disposed of 4,413 shares of Omada Health common stock at a price of $24.28 per share. After the sale his reported direct beneficial ownership is 140,323 shares. The filing also reports 861,109 shares held indirectly in family trusts for the benefit of his family, which he disclaims beneficial ownership of except to the extent of any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 09/09/2025.
FAQ
What is the current stock price of OMADA HEALTH (OMDA)?
What is the market cap of OMADA HEALTH (OMDA)?
